Search
Enter keywords, a title or a report id number below.
Your Search for 'Drug Discovery for Nervous System Diseases' returned 110 results - Page 1 of 6
Sort by
Sorted by
Rank
Top-Bottom
-
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 355: Factors that increase the permeability of the BBB Table 2-5: Diseases that affect the BBB Table 3-1: Various methods of drug delivery to the central nervous system Table 3-2: Drugs available for ... -
Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize Therapeutic Outcomes
GBI Research, Nov 2012 , Pages: 87process. The report describes the history of biomarkers and their role in fulfilling the unmet needs of the conventional drug discovery process. The drivers and barriers for the biomarkers market, along ... -
Drug Discovery and Preclinical Molecules by Therapy Area - Innovation Focuses on Stem Cell Therapies and Gene Therapies
GBI Research, Feb 2011 , Pages: 209Challenge to Pharmaceutical Companies 5.1 Drug Discovery & Development Process 5.1.1 Drug Discovery Process 6 Drug Discovery and Preclinical Molecules in Therapeutic Segments 6.1 Central Nervous System ... -
Proteomics - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 631in application of proteomics to oncology 9. Neuroproteomics Introduction Application of proteomics for the study of nervous system Proteomics of prion diseases Normal function of prions in the ... -
Drug Discovery for Nervous System Diseases
John Wiley and Sons Ltd, Nov 2004 , Pages: 320Drug Discovery for Nervous System Diseases The neurosciences have been an especially difficult field for drug discovery. Because of the huge complexity of the nervous system and poor understanding of ... -
Biomarkers - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 920nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics ... -
Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
GBI Research, Feb 2011 , Pages: 209Challenge to Pharmaceutical Companies 27 5.1 Drug Discovery & Development Process 27 5.1.1 Drug Discovery Process 27 6 Early Stage Drug Discovery in Therapeutic Segments 28 6.1 Central Nervous System ... -
Strategic Development of Neural Stem & Progenitor Cell Products
BioInformant, Jan 2012 , Pages: 113neurogenesis is responsible for populating the growing brain. Neural stem cells (NSCs) are the self-renewing, multipotent cells that differentiate into the main phenotypes of the nervous system. These cell types ... -
UK/Ireland Biotechnology Sector: Clinical Phase Drug Development Pipeline
Beremans Limited, Sep 2011 , Pages: 50base is located in the UK. - ‘Drug candidates’ means chemical or biological entities intended for the prevention or treatment of medical problems in humans. Therefore, the report does not include UK ... -
GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
GBI Research, Nov 2011 , Pages: 143Avenues 35 4.7.4 Case Studies 35 5 GPCRs in Drug Discovery – Orphan GPCRs 36 5.1 Introduction 36 5.1.1 Orphan GPCRs in the GRAFS Classification System 36 5.1.2 Orphan GPCRs in the Traditional Classification ... -
RNAi - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 498heart disease miRNAs as therapeutic targets for cardiovascular diseases Concluding remarks and future prospects of miRNA in the cardiovascular system Role of miRNAs in the nervous system miRNAs and ... -
Nitric Oxide - Therapeutics, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 276tables and 25 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated ... -
Cell Therapy - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 1050system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints ... -
Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report
NeuroInsights, Nov 2012 , Pages: 200innovative research and development in stem cell technology for the brain and nervous system provides unique insights into the key players, cutting edge science and investment opportunities in this rapidly ... -
TransTech Pharma Inc.
Sheila Greco Associates, May 2011 , Pages: 1pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including cardiovascular disorders, central nervous system disorders, type III ... -
Antiviral Therapeutics - Technologies, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 501of antiviral therapies 2. Antiviral Approaches Classification Antiviral drug discovery and development Viral versus cellular targets for antiviral therapy Antivirals based on double-stranded RNA ... -
Pain Therapeutics - Drugs, Markets and Companies
Jain PharmaBiotech, May 2013 , Pages: 544molecular elements of pain in the central nervous system Table 2-1: IASP guidelines for the use of animals in pain studies Table 2-2: Chronic pain as a manifestation of other diseases Table 2-3 ... -
Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
GBI Research, Jul 2012 , Pages: 44areas primarily targeted by these types of molecules, such as Central Nervous System (CNS), cardiovascular, immunology, musculoskeletal diseases, ophthalmology, infectious diseases, dermatology as well as ... -
Licensing Opportunities: Neurology
Decision Resources, Inc, Apr 2010 , Pages: 35drug markets and neurology R&D; insights on the Alzheimer’s disease market from Matthew Winton, Ph.D., a Decision Resources analyst specializing in central nervous system diseases. - Primary data ... -
Motor Neurone Diseases - Pipeline Review, H2 2011
Global Markets Direct, Aug 2011 , Pages: 196Enrollment Of First Patient In Global Phase III Study Of Dexpramipexole For ALS Mar 09, 2011: Neuralstem's Human Stem Cells Integrate Into Nervous System Of Rats With Animal Model Of ALS Feb 20, 2011 ...
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
